{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:38:50Z","timestamp":1789951130836,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T00:00:00Z","timestamp":1428710400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1298-6","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T03:14:23Z","timestamp":1428722063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity"],"prefix":"10.1186","volume":"15","author":[{"given":"Sasha E","family":"Stanton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen M","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Christos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta V","family":"Cobham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J","family":"Scheff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Cigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda T","family":"Vahdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen E","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,11]]},"reference":[{"issue":"3","key":"1298_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/sj.clpt.6100087","volume":"81","author":"KM Giacomini","year":"2007","unstructured":"Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007;81(3):328\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1298_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med"},{"issue":"31","key":"1298_CR3","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1298_CR4","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215\u201321.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1298_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","volume":"37","author":"T Chen","year":"2011","unstructured":"Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev. 2011;37(4):312\u201320.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1298_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459\u201365.","journal-title":"Nat Med"},{"issue":"13","key":"1298_CR7","doi-asserted-by":"publisher","first-page":"8880","DOI":"10.1073\/pnas.122249299","volume":"99","author":"C Ozcelik","year":"2002","unstructured":"Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99(13):8880\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6555","key":"1298_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/378394a0","volume":"378","author":"KF Lee","year":"1995","unstructured":"Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378(6555):394\u20138.","journal-title":"Nature"},{"issue":"2","key":"1298_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.breast.2010.11.002","volume":"20","author":"A Zambelli","year":"2011","unstructured":"Zambelli A, Della Porta MG, Eleuteri E, De Giuli L, Catalano O, Tondini C, et al. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast. 2011;20(2):176\u201383.","journal-title":"Breast"},{"issue":"23","key":"1298_CR10","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","volume":"25","author":"ML Telli","year":"2007","unstructured":"Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25(23):3525\u201333.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1298_CR11","first-page":"1109","volume":"12","author":"KG Montgomery","year":"2003","unstructured":"Montgomery KG, Gertig DM, Baxter SW, Milne RL, Dite GS, McCredie MR, et al. The HER2 I655V polymorphism and risk of breast cancer in women\u2009<\u2009age 40\u00a0years. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1109\u201311.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"1298_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/01.ede.0000083227.74669.7b","volume":"14","author":"JL Rutter","year":"2003","unstructured":"Rutter JL, Chatterjee N, Wacholder S, Struewing J. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology. 2003;14(6):694\u2013700.","journal-title":"Epidemiology"},{"issue":"6","key":"1298_CR13","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/annonc\/mdu111","volume":"25","author":"X Han","year":"2014","unstructured":"Han X, Diao L, Xu Y, Xue W, Ouyang T, Li J, et al. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. Ann Oncol. 2014;25(6):1158\u201364.","journal-title":"Ann Oncol"},{"issue":"13","key":"1298_CR14","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1158\/1078-0432.CCR-04-2208","volume":"11","author":"W Han","year":"2005","unstructured":"Han W, Kang D, Lee JE, Park IA, Choi JY, Lee KM, et al. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin Cancer Res. 2005;11(13):4775\u20138.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1298_CR15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/jnci\/92.5.412","volume":"92","author":"D Xie","year":"2000","unstructured":"Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, et al. Population-based, case\u2013control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2000;92(5):412\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1298_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/annonc\/mdm181","volume":"18","author":"S Beauclair","year":"2007","unstructured":"Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol. 2007;18(8):1335\u201341.","journal-title":"Ann Oncol"},{"issue":"3","key":"1298_CR17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10549-010-0886-z","volume":"124","author":"S Lu","year":"2010","unstructured":"Lu S, Wang Z, Liu H, Hao X. HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case\u2013control studies. Breast Cancer Res Treat. 2010;124(3):771\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"1\u20132","key":"1298_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jns.2012.12.017","volume":"325","author":"V Wang","year":"2013","unstructured":"Wang V, Chuang TC, Kao MC, Shan DE, Soong BW, Shieh TM. Polymorphic Ala-allele carriers at residue 1170 of HER2 associated with Parkinson\u2019s disease. J Neurol Sci. 2013;325(1\u20132):115\u20139.","journal-title":"J Neurol Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1298-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1298-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T12:37:47Z","timestamp":1551184667000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1298-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,11]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1298-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,11]]},"article-number":"267"}}